2015
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009
Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology 2015, 1: 1098. PMID: 26313372, DOI: 10.1001/jamaoncol.2015.2722.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenetic TestingGuideline AdherenceHumansInsurance BenefitsMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPatient SelectionPhenotypePractice Guidelines as TopicPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsReceipt of chemotherapyLower chemotherapy useHigh-risk diseasePatients 70 yearsChemotherapy useBreast cancerRecurrence scoreMedicare beneficiariesNational Comprehensive Cancer Network guidelinesEarly-stage breast cancerConsideration of chemotherapyLow-risk diseaseOverall chemotherapy useIncident breast cancerLow-risk patientsRetrospective cohort studyHigh-risk patientsPrespecified subgroup analysisUse of chemotherapyAdditional prognostic informationEnd Results (SEER) dataInvasive breast cancerRS assayNCCN riskAdjuvant chemotherapyResource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer
Dinan MA, Li Y, Zhang Y, Stewart SB, Curtis LH, George DJ, Reed SD. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: 28-37.e2. PMID: 26382223, PMCID: PMC4698191, DOI: 10.1016/j.clgc.2015.07.006.Peer-Reviewed Original ResearchConceptsEnd Results-Medicare dataEnd of lifeProstate cancerOutpatient settingOutpatient useRetrospective analysisMore hospicesLower mean inpatient costsSkilled nursing facility daysIntensive care unit daysIntensive care unit useJudicious careAndrogen deprivation therapyOverall health care costsUse of chemotherapyMean inpatient costsMultiple invasive proceduresHealth care costsSignificant financial burdenDeprivation therapyNoncancer causesICU useSingle strongest predictorUnit daysInpatient costs
2012
Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer.
Reed S, Dinan M, Schulman K, Lyman G. Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 1525-1525. DOI: 10.1200/jco.2012.30.15_suppl.1525.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioEstrogen receptor-positive breast cancerReceptor-positive breast cancerUse of chemotherapyRecurrence scoreBreast cancerRisk groupsEarly-stage breast cancerPatient time costsDirect medical costsLifetime direct medical costsQuality-adjusted survivalCost-effectiveness ratioHealthcare system perspectiveLower indirect costsMultifactorial decisionDecision analytic modelProbabilistic sensitivity analysesCost-effectiveness estimatesDistant recurrenceHormonal therapyClinicopathologic characteristicsDisease recurrenceAttributable costsMedical costs